Investment Rating - Industry Rating: Recommended [3] Core Insights - The pork price center continues to decline, with the average price of live pigs dropping to 12.79 CNY/kg, a week-on-week decrease of 3.55% [2][15] - The agricultural sector is focusing on enhancing grain and oil production capabilities, emphasizing agricultural technology innovation and socialized services [1][14] - The report suggests that the commercialization of genetically modified crops will accelerate, improving self-sufficiency rates for key varieties [1][14] Summary by Sections Planting Industry Chain - The National Agricultural Development Center and the Ministry of Agriculture held a meeting to enhance grain and oil production capabilities, emphasizing the role of agricultural technology and social services [1][14] - Key companies benefiting from this trend include Beidahuang and Suqian Agricultural Development [1][14] Swine Farming - The current market is oversupplied, leading to a continuous decline in pig prices [2][15] - The Ministry of Agriculture plans to reduce the breeding sow inventory by approximately 1 million heads, aiming for a total of about 39.5 million heads [2][15] - Recommended stocks in the swine sector include Muyuan Foods, Wens Foodstuffs, and others [5][15] Key Companies and Stock Recommendations - Recommended stocks in the breeding sector include: - Muyuan Foods - Wens Foodstuffs - DeKang Agriculture - Jingji Smart Agriculture [5][15] - In the feed sector, HaiDa Group is highlighted as a key player [5][15] - In the animal health sector, companies like Jinhe Biology and Zhongmu Co. are expected to benefit [5][15]

Market Overview - On September 19, the animal health sector declined by 0.26% compared to the previous trading day, with the driving force leading the decline [1] - The Shanghai Composite Index closed at 3820.09, down 0.3%, while the Shenzhen Component Index closed at 13070.86, down 0.04% [1] Stock Performance - Notable stock movements included: - *ST Lvkang (002868): Closed at 27.56, up 4.99% with a trading volume of 38,500 shares and a turnover of 105 million yuan [1] - Kexin Biological (688526): Closed at 18.08, up 0.39% with a trading volume of 22,700 shares and a turnover of 40.94 million yuan [1] - Driving Force (838275): Closed at 10.50, down 4.11% with a trading volume of 21,200 shares and a turnover of 22.63 million yuan [2] Capital Flow - The animal health sector experienced a net outflow of 91.4 million yuan from institutional investors, while retail investors saw a net inflow of 70.15 million yuan [2] - The capital flow for individual stocks showed: - RuiPu Biological (300119): Net inflow of 16.56 million yuan from institutional investors, but a net outflow of 21.57 million yuan from retail investors [3] - *ST Lvkang (002868): Net inflow of 6.13 million yuan from institutional investors, with a net outflow of 4.21 million yuan from retail investors [3]

Market Overview - On September 18, the animal health sector declined by 0.77% compared to the previous trading day, with Huisheng Biological leading the decline [1] - The Shanghai Composite Index closed at 3831.66, down 1.15%, while the Shenzhen Component Index closed at 13075.66, down 1.06% [1] Stock Performance - The following stocks in the animal health sector showed notable performance: - *ST Lvkang (002868): Closed at 26.25, up 5.00% with a trading volume of 3433 lots [1] - Shengbi Biological (600201): Closed at 66.8, down 2.39% with a trading volume of 55.74 million [1] - Ruipu Biological (300119): Closed at 22.06, unchanged with a trading volume of 111.3 million [1] - Other stocks such as Jinhai Biological (002688) and Shunlian Biological (688098) also experienced declines of 1.98% and 2.02% respectively [1][2] Capital Flow - The animal health sector experienced a net outflow of 126 million yuan from institutional investors, while retail investors saw a net inflow of 92.38 million yuan [2] - The following stocks had significant capital flow: - Ruipu Biological: Net inflow of 12.35 million yuan from institutional investors [3] - *ST Lvkang: Net outflow of 3.83 million yuan from institutional investors [3] - Jinhai Biological: Net outflow of 25.51 million yuan from institutional investors [3]

Market Overview - The animal health sector experienced a decline of 0.32% on September 17, with Shunlian Biological leading the drop [1] - The Shanghai Composite Index closed at 3876.34, up 0.37%, while the Shenzhen Component Index closed at 13215.46, up 1.16% [1] Individual Stock Performance - ST Lvkang (002868) saw a closing price of 25.00, with a rise of 5.00% and a trading volume of 28,300 lots, totaling a transaction value of 67.72 million [1] - Ruipu Biological (300119) closed at 22.06, up 0.32%, with a trading volume of 78,100 lots and a transaction value of 172 million [1] - Kexin Biological (688526) closed at 18.39, with a slight increase of 0.05% and a trading volume of 30,000 lots, totaling 55.44 million [1] - Other notable declines include Yongshun Biological (10.40, -0.19%), Zhongmu Co. (7.38, -0.27%), and Haili Biological (7.15, -0.28%) [1] Capital Flow Analysis - The animal health sector saw a net outflow of 72.39 million from institutional investors, while retail investors contributed a net inflow of 31.00 million [2] - The overall capital flow indicates a mixed sentiment, with institutional investors pulling back while retail investors showed interest [2] Detailed Capital Flow for Selected Stocks - Ruipu Biological had a net inflow of 3.75 million from institutional investors, but a net outflow of 5.98 million from retail investors [3] - ST Lvkang experienced a net inflow of 2.05 million from institutional investors, with retail investors showing a slight outflow [3] - Shunlian Biological faced a significant net outflow of 20.09 million from institutional investors, while retail investors contributed a net inflow of 13.17 million [3]

证券代码：603566 证券简称：普莱柯 公告编号：2025-038 普莱柯生物工程股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 本次会议是否有否决议案：无 一、会议召开和出席情况 (一)股东大会召开的时间：2025年9月16日 (二)股东大会召开的地点：河南省洛阳市洛龙区政和路15号公司二楼会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： (五)公司董事、监事和董事会秘书的出席情况 3、董事会秘书出席会议；部分高级管理人员列席会议。 二、议案审议情况 (一)非累积投票议案 1、议案名称：关于公司 2025 年半年度利润分配方案的议案 审议结果：通过 表决情况： ■ ■ (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 会议由公司董事会召集，由董事长张许科先生主持，本次会议以现场投票与网络投票相结合的方式召 开，北京德恒律师事务所律师出席了现场会议并见证。本次会议的召集、召开符合《公司法》《公司章 程》等 ...

法律意见 北京德恒律师事务所 DeHeng Law Offices 北京德恒律师事务所 关于普莱柯生物工程股份有限公司 2025 年第一次临时股东大会的 北京市西城区金融街 19 号富凯大厦 B 座 12 层 电话:010-52682888 传真:010-52682999 邮编:100033 北京德恒律师事务所 关于普莱柯生物工程股份有限公司 2025 年第一次临时股东大会的法律意见 北京德恒律师事务所 关于普莱柯生物工程股份有限公司 2025 年第一次临时股东大会的 法律意见 德恒 01G20240892-02 号 致: 普莱柯生物工程股份有限公司 北京德恒律师事务所受普莱柯生物工程股份有限公司（以下简称"普莱柯" 或"公司"）委托,指派赖元超律师、王凯妮律师(以下简称"本所律师") 出 席普莱柯 2025年第一次临时股东大会(以下简称"本次股东大会")，对本次 股东大会的合法性进行见证并出具法律意见。 本所及本所律师根据《中华人民共和国证券法》(以下简称"《证券法》")、 《律师事务所从事证券法律业务管理办法》和《律师事务所证券法律业务执业规 则(试行)》的规定及本法律意见出具日以前已经发生或者存在的事实 ...

证券代码：603566 证券简称：普莱柯 公告编号：2025-038 普莱柯生物工程股份有限公司 2025年第一次临时股东大会决议公告 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 9 月 16 日 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： (二) 股东大会召开的地点：河南省洛阳市洛龙区政和路 15 号公司二楼会议室 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 271 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 125,458,862 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股份 | | | 总数的比例（%） | 36.6925 | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 会议由公司董事会召集，由董事长张许科先生主持，本次会议以现场投票与 网络投票相结合的方式召开，北京德恒律师事务所律师出席了现场会 ...

Market Overview - On September 16, the animal health sector declined by 0.41%, with *ST Lvkang leading the drop [1] - The Shanghai Composite Index closed at 3861.87, up 0.04%, while the Shenzhen Component Index closed at 13063.97, up 0.45% [1] Stock Performance - Key stocks in the animal health sector showed mixed performance, with the following notable movements: - Xianfeng Holdings (002141) increased by 2.27% to close at 4.06 [1] - Haili Biological (603718) rose by 1.27% to 7.17 [1] - *ST Lvkang (002868) fell by 4.34% to 23.81, leading the decline [2] - The trading volume and turnover for selected stocks were significant, with Xianfeng Holdings achieving a turnover of 1.02 billion [1] Capital Flow Analysis - The animal health sector experienced a net outflow of 15.97 million from institutional investors, while retail investors saw a net inflow of 11.29 million [2][3] - Notable capital flows included: - Biological Shares (600201) had a net inflow of 12.28 million from institutional investors [3] - *ST Lvkang (002868) saw a net outflow of 2.89 million from institutional investors [3] - Retail investors contributed positively to several stocks, including a net inflow of 12.59 million into Shenyuan Biological (688098) [3]

Company Overview - Pulaike Bioengineering Co., Ltd. is located in Luoyang, Henan Province, established on June 22, 2002, and listed on May 18, 2015. The company primarily engages in the research, production, sales, and related technology transfer of veterinary biological products, chemical drugs, and traditional veterinary medicine [1][2]. Financial Performance - For the first half of 2025, Pulaike achieved operating revenue of 559 million yuan, representing a year-on-year growth of 15.79%. The net profit attributable to the parent company was 116 million yuan, reflecting a significant increase of 57.12% [2]. - Since its A-share listing, Pulaike has distributed a total of 1.057 billion yuan in dividends, with 500 million yuan distributed over the past three years [3]. Stock Performance - As of September 16, Pulaike's stock price decreased by 2.07% to 14.21 yuan per share, with a total market capitalization of 4.918 billion yuan. The stock has seen a year-to-date increase of 14.92%, but has declined by 1.93% over the last five trading days and 6.76% over the last twenty days [1]. - The stock's trading volume on September 16 was 32.122 million yuan, with a turnover rate of 0.65% [1]. Shareholder Information - As of June 30, 2025, Pulaike had 18,000 shareholders, an increase of 4.27% from the previous period. The average circulating shares per person decreased by 4.09% to 19,234 shares [2]. - Among the top ten circulating shareholders, the Guotai Zhongzheng Livestock Breeding ETF (159865) ranked as the seventh largest, holding 3.4499 million shares, an increase of 141,400 shares from the previous period [3]. Business Segments - Pulaike's main business revenue composition includes: poultry vaccines and antibodies (41.19%), pig vaccines (32.25%), chemical drugs (21.37%), functional health products (1.79%), pet vaccines (1.38%), and other income sources [1].

Investment Rating - The industry investment rating is "Positive" [3] Core Viewpoints - The report highlights that the agricultural sector is experiencing a recovery, with specific segments such as the pig and beef industries showing signs of improvement. Cost reduction and efficiency enhancement are key drivers for performance improvement in the pig sector, while the beef sector is witnessing a rebound from a cyclical low [6][7][47]. Summary by Sections 1. Pig Industry - The pig sector has shown significant improvement in performance, with 15 listed pig companies achieving a revenue of 196.98 billion yuan in the first half of 2025, a year-on-year increase of 19%. The net profit attributable to shareholders reached 16.33 billion yuan, up 625% year-on-year [9]. - The average pig price has been under pressure, dropping to a low of 13.96 yuan/kg in June 2025. However, leading companies like Muyuan and Wens continue to maintain high profitability per head due to their efficiency advantages [15][42]. - Recommendations include focusing on low-cost, high-certainty leaders such as Muyuan and Wens, as well as high-growth small pig companies like Shennong Group and Juxing Agriculture [7][43]. 2. Beef Industry - The beef sector is experiencing a cyclical recovery, with live cattle prices increasing significantly since mid-February 2025. As of September 8, 2025, the prices for fattened bulls, calves, and cull cows have risen by 2.39, 8.33, and 3.18 yuan/kg respectively [47]. - The report notes that the overall beef market is supported by a trend towards protein upgrading, which is expected to continue despite economic fluctuations [57]. 3. Animal Health Sector - The animal health sector is stabilizing, with a focus on the development of pet business. The rapid release of pet vaccines is anticipated to enhance valuations across companies [7]. 4. Seed Industry - The seed market is shifting from quantity to quality competition, with a focus on superior varieties as the core competitiveness of seed companies. The report emphasizes the importance of resource integration and mergers in the seed industry [7]. Companies with strong variety reserves, such as Dabeinong and Longping High-Tech, are expected to benefit [7].